Key result
Immunosuppressive therapy enables ECMO weaning in ~67% of patients with autoimmune-mediated fulminant myocarditis.
Why the study?
Does immunosuppressive therapy facilitate recovery and ECMO weaning in patients with autoimmune-mediated fulminant myocarditis?
Case Report (n=3)
No
Does immunosuppressive therapy facilitate recovery and ECMO weaning in patients with autoimmune-mediated fulminant myocarditis?
Combined immunosuppression may promote myocardial recovery and enable successful ECMO weaning in select patients presenting with fulminant myocarditis secondary to autoimmune disease.
Answers are grounded in this paper and cite their sources.
May aid ECMO weaning in select autoimmune fulminant myocarditis; hypothesis-generating and requires prospective validation before practice change.
Myocarditis is a potentially life-threatening inflammatory disease of the myocardium, often resulting from infectious and immune-mediated responses. Clinical presentation in severe cases often results in a devastating illness requiring extracorporeal membrane oxygenation support as a result of cardiogenic shock. Although endomyocardial biopsy is still considered the gold standard for diagnosis, it often reveals nonspecific lymphocytic infiltration. Because the precise cause is usually unknown, the initial treatment typically involves immunosuppression and frequent assessment of myocardial contractility. This report presents 3 rare cases of autoimmune diseases (polymyositis, immunoglobulin G4-related disease, and systemic lupus erythematosus) that require extracorporeal membrane oxygenation support as a result of fulminant myocarditis, including their follow-up periods.
No takes yet. Share an insight, caveat, or question.
Depta et al. (2024) conducted a case report in Fulminant myocarditis in autoimmune disease requiring ECMO (n=3). Immunosuppression and ECMO was evaluated on Recovery and ECMO weaning.
Synapse has enriched 10 related papers. Consider them for comparative context: